A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Boston MA, Baltimore MD, Washington D.C. DC, Fairfax VA,
Sponsor: Puma Biotechnology, Inc.
Sex: All
Age: 18+
Code: NCT06095505
Phase2, Recruiting
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
for
Lung Cancer, Lung Cancer Metastatic, Brain Metastases,
Location: Sacramento CA
Sponsor: University of California, Davis
Sex: All
Age: 18+
Code: NCT05452005
Phase1, Recruiting
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Location: Montreal, Baltimore MD, Fairfax VA, Houston TX,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT04686305
Phase1, Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
for
Ovarian Cancer, Non-small Cell Lung Cancer
Location: New York NY, East Brunswick NJ, Fairfax VA, Columbus OH,
Sponsor: Tubulis GmbH
Sex: All
Age: 18+
Code: NCT06303505
Phase1, Phase2, Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
for
Non Small Cell Lung Cancer,
Location: Boston MA, Austin, TX 78758 TX, San Antonio TX
Sponsor: Zumutor Biologics Inc.
Sex: All
Age: 18+
Code: NCT06451497
Phase1, Recruiting
Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
for
Non Small Cell Lung Cancer
Location: Waltham MA
Sponsor: Sanguine Biosciences
Sex: All
Age: 18 - 70+
Code: NCT05669105
Recruiting
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
for
Non-small Cell Lung Cancer
Location: Boston MA, New York NY, Fairfax VA, Los Angeles CA
Sponsor: RedCloud Bio
Sex: All
Age: 18+
Code: NCT05519293
Phase1, Phase2, Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
for
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Location: Bethesda MD, Orange City FL, Toledo OH, Grand Rapids MI,
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Sex: All
Age: 18+
Code: NCT06095583
Phase3, Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
for
Non-small Cell Lung Cancer
Location: New Haven CT, Brooklyn NY, New York NY, Montreal,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06350097
Phase3, Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
for
Non-Small Cell Lung Cancer
Location: St. John's, Rimouski, Boston MA, Levis, Stony Brook NY,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06357533
Phase3, Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
for
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer,
Location: Boston MA, New York NY, Fairfax VA, Pittsburgh PA,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT06128551
Phase1, Phase2, Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
for
Breast Cancer, Gastric Cancer, Esophageal Cancer,
Location: New York NY, Nashville TN, Houston TX, Dallas TX,